Breaking News
Get 55% Off 0
Selloff or Market Correction? Either Way, Here's What to Do Next
See Overvalued Stocks
Close

MRNA 80.82SPLOPENS (DE000SD09YZ9)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
MRNA 80.82SPLOPENS historical data, for real-time data please try another search
0.720 0.000    0.00%
16/10 - Closed. Currency in
Type:  Certificate
Market:  France
ISIN:  DE000SD09YZ9 
Underlying:  Moderna
Asset Class:  Equity
  • Volume: 0
  • Bid/Ask: 0.000 / 0.000
  • Day's Range: 0.585 - 1.130
MRNA 80.82SPLOPENS 0.720 0.000 0.00%

DE000SD09YZ9 News

 
The latest news and headlines about the MRNA 80.82SPLOPENS certificate.
Moderna's chief legal officer sells shares worth $23,637
Moderna's chief legal officer sells shares worth $23,637 By Investing.com - Dec 10, 2024

CAMBRIDGE, MA—Shannon Thyme Klinger, the Chief Legal Officer of Moderna , Inc. (NASDAQ:MRNA), sold 529 shares of the company's common stock on December 9, 2024. The shares were sold at an...

BofA reinstates pharma coverage
BofA reinstates pharma coverage By Investing.com - Dec 10, 2024

Investing.com -- Bank of America reinstated coverage of 11 major U.S. pharmaceutical and biotech stocks in a note Tuesday, highlighting mixed sector fundamentals. While innovation potential in disease...

Moderna chief legal officer sells $4,849 in stock
Moderna chief legal officer sells $4,849 in stock By Investing.com - Dec 04, 2024

Shannon Thyme Klinger, Chief Legal Officer at Moderna , Inc. (NASDAQ:MRNA), reported a recent stock transaction involving the sale of company shares. On December 3, Klinger sold 112 shares of...

Moderna president Stephen Hoge sells shares worth $13,595
Moderna president Stephen Hoge sells shares worth $13,595 By Investing.com - Dec 04, 2024

CAMBRIDGE, MA—Stephen Hoge, President of Moderna , Inc. (NASDAQ:MRNA), recently executed stock transactions as detailed in a Form 4 filing with the SEC. On December 3, Hoge sold 314 shares of...

Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

DE000SD09YZ9 Comments

Write your thoughts about MRNA 80.82SPLOPENS
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Apple
Continue with Google
or
Sign up with Email